David Finkelstein, MD
Dermatology · Voorhees, NJNPI 1518034628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 1,724 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.
Across 1,724 payments — averaging $12.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$3K
- AbbVie$2K
- Almirall LLC$2K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$2K
- Galderma Laboratories, L.p.$2K
- UCB, Inc.$1K
- plus $9K from 28 others
What the payments were for
- Consulting fees$1,3136%
- Food & beverage$19,27391%
- Education$5973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 208 | $2,521 |
| AbbVie | 167 | $2,089 |
| Almirall LLC | 154 | $1,998 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 195 | $1,895 |
| Galderma Laboratories, L.p. | 40 | $1,746 |
| UCB, Inc. | 172 | $1,476 |
| Novartis | 106 | $1,199 |
| E.r. Squibb & Sons, L.L.C. | 124 | $1,112 |
| Lilly USA, LLC | 77 | $1,008 |
| LEO Pharma Inc. | 77 | $992 |
| Pfizer | 40 | $546 |
| Johnson & Johnson | 19 | $472 |
| Regeneron Healthcare Solutions, Inc. | 30 | $454 |
| Amgen | 31 | $417 |
| Incyte Corporation | 29 | $412 |
| Mayne Pharma Commercial LLC | 35 | $370 |
| Organon | 38 | $363 |
| Arcutis Biotherapeutics, Inc. | 26 | $337 |
| Dermavant Sciences, Inc. | 42 | $324 |
| Sanofi | 17 | $241 |
| Bristol Myers Squibb | 26 | $206 |
| EPI Health, LLC | 10 | $183 |
| Journey Medical Corporation | 13 | $180 |
| VYNE Pharmaceuticals Inc. | 12 | $146 |
| Dermira, Inc. | 11 | $141 |
| Sandoz | 6 | $82 |
| Sebela Pharmaceuticals Inc. | 5 | $68 |
| Encore Dermatology Inc. | 5 | $68 |
| Botanix SB Inc | 2 | $33 |
| Fresenius Kabi USA, LLC | 2 | $30 |
| Aclaris Therapeutics, Inc. | 2 | $29 |
| Mylan Institutional Inc. | 1 | $16 |
| Promius Pharma LLC | 1 | $14 |
| Taro Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORACEA$1,313
How this compares
$21,182 in reported general payments places this provider in the 85th percentile of 394 dermatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 196 | $769,501 |
| Cimzia (2 Pack)Certolizumab Pegol | 22 | $291,778 |
| IlumyaTildrakizumab-Asmn | 15 | $249,895 |
| OtezlaApremilast | 28 | $133,944 |
| Humira(Cf) PenAdalimumab | 15 | $119,233 |
| Humira(Cf)Adalimumab | 12 | $80,048 |
| Dupixent SyringeDupilumab | 12 | $50,607 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 200 | $11,133 |
| Ketoconazole | 329 | $7,711 |
| Pimecrolimus | 15 | $3,803 |
| Metronidazole | 74 | $3,432 |
| Tretinoin | 68 | $3,134 |
| Doxycycline Monohydrate | 115 | $2,836 |
| Tacrolimus | 37 | $2,235 |
| Triamcinolone Acetonide | 151 | $1,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $1,476 | $291,77822 claims |
| Sun Pharmaceutical Industries Inc.Ilumya | $2,521 | $249,89515 claims |
| AmgenOtezla | $417 | $133,94428 claims |
| AbbVieHumira(Cf) | $2,089 | $80,04812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 394 dermatology providers in New Jersey.
Other dermatology in Voorhees
- Ronald BernardinVoorhees$688K
- Omar NoorSomerset$4.5M
- Linda Cappiello-LindsleyHoboken$2.3M
- Brian KeeganEast Windsor$1.7M
- Jerry BagelEast Windsor$1.6M
- Mital Patel CohenFlorham Park$799K
- Brian MachlerFlorham Park$346K
- Jeanine DownieMontclair$327K
- Aanand GeriaRutherford$251K
- Jason MillerFreehold$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.